NuCana(NCNA) - 2025 Q4 - Annual Report

Financial Performance - The company incurred net losses of £29.4 million for the year ended December 31, 2025, and has an accumulated deficit of £252.3 million as of the same date[45]. - The company has an accumulated deficit totaling £252.3 million and cash flows used in operating activities of £7.5 million for the year ended December 31, 2025[68]. - As of December 31, 2025, the company had £24.3 million in cash and cash equivalents, which is expected to fund operations for at least the next twelve months[64]. - The company anticipates substantial additional funding will be required to complete the development and commercialization of its product candidates[63]. - The company may need to raise additional funds if it chooses to pursue additional indications or geographies for its product candidates[68]. Product Development and Clinical Trials - Product candidate NUC-7738 is currently in the Phase 2 part of a Phase 1/2 clinical trial for patients with advanced solid tumors, while NUC-3373 is being evaluated in a Phase 1b/2 modular clinical trial[45]. - The company has invested substantially in the development of NUC-7738 and NUC-3373, with no revenues expected for at least the next several years[51]. - The company is conducting a Phase 1/2 clinical trial (NuTide:701) evaluating NUC-7738, with a focus on advanced solid tumors and PD-1 inhibitor-resistant melanoma[109]. - The company is also running a Phase 1b/2 modular clinical trial (NuTide:303) for NUC-3373 in combination with pembrolizumab and docetaxel for advanced solid tumors and lung cancer, respectively[109]. - Clinical trials may face delays due to difficulties in patient enrollment and site initiation, impacting overall development timelines[92]. Regulatory Challenges - The company plans to seek regulatory approval for NUC-7738 and NUC-3373 in the United States and the European Union, facing varying regulatory requirements across jurisdictions[57]. - The company has not submitted any New Drug Applications (NDA) or Marketing Authorization Applications (MAA) for its product candidates and does not expect to do so in the foreseeable future[56]. - The company may face significant delays or inability to commercialize NUC-7738 and NUC-3373 if it does not overcome regulatory and clinical trial challenges[55]. - Regulatory approval processes may be delayed due to disagreements with the FDA regarding clinical trial designs and data interpretations, as highlighted by the FDA's 2022 guidance on "Project Optimus"[112]. - The company faces challenges in obtaining marketing approvals in foreign markets due to varying regulatory requirements and potential delays in the approval process[169]. Competition and Market Risks - The company faces substantial competition, which may impact the commercialization of its product candidates[43]. - The company anticipates that competition from major pharmaceutical and biotechnology companies will be substantial, particularly in the cancer treatment market[210]. - The potential for significant competition exists, particularly for the company's product candidates NUC-7738 and NUC-3373, which would compete with existing therapies and generics[211]. - The company faces significant competition from larger firms with greater financial resources and expertise in R&D, manufacturing, and marketing, which may hinder its market entry and position[215]. Operational and Compliance Risks - The company must establish a robust supply chain and seek marketing approvals for its product candidates that successfully complete pivotal clinical trials[52]. - The company relies on third-party contract manufacturers for the production and shipment of its product candidates, increasing risks related to supply and quality control[191]. - Compliance with anti-corruption laws, such as the U.K. Bribery Act and the U.S. FCPA, is essential, as violations could lead to significant penalties and impact the company's financial condition[179]. - Environmental, health, and safety regulations impose additional compliance costs, and failure to adhere could result in substantial fines and operational impairments[180]. - The company is subject to stringent data privacy regulations, including GDPR and U.K. GDPR, which impose compliance burdens and potential liabilities related to personal data handling[117]. Financial and Market Conditions - Inflation and tariffs may increase the company's overall cost structure, adversely affecting liquidity and financial condition[82]. - Unstable market conditions have led to extreme volatility in financial markets, potentially making capital raising more difficult and costly[96]. - Future government shutdowns could impact the company's access to public markets and necessary capital, affecting operational continuity[72]. - Changes in the tax system could materially affect the company's financial condition and results of operations, increasing estimated tax liabilities[80]. Intellectual Property and Legal Risks - The company must maintain adequate intellectual property protection to prevent competitors from commercializing similar technologies, which is crucial for successful product commercialization[229]. - The patent portfolio includes both patents and applications, which are essential for protecting proprietary technology and products[230]. - Cybersecurity incidents pose risks to the company's data integrity and could disrupt product development programs, leading to potential legal and financial repercussions[222]. - The company may face increased litigation against regulatory agencies due to recent U.S. Supreme Court decisions, creating uncertainty in regulatory compliance[74]. Marketing and Sales Challenges - The company currently lacks a marketing capability or sales force, which may impede its ability to effectively sell or market approved product candidates[220]. - Establishing a sales and marketing team is costly and time-consuming, and any delays in commercialization could result in lost investments[220]. - Coverage and reimbursement decisions for new medicines in the U.S. are primarily made by CMS, with private payors often following CMS guidelines, making reimbursement uncertain[217]. - Delays in obtaining reimbursement for newly approved drugs may limit coverage and impact the company's ability to recover costs associated with research and development[218].